Clinical Study
RyR2 QQ2958 Genotype and Risk of Malignant Ventricular Arrhythmias
Table 6
Clinical characteristics and events stratified according to RyR2 allele status.
| | | RyR2 QQ
| RyR2 QR + RR
| value |
| | Demographic | | | | | Male sex, (%) | 13 (72.2%) | 170 (78.3%) | 0.5581 | | Age (years) | 74 ± 7 | 72 ± 6 | 0.1811 | | BMI (kg/m2) | 28 ± 6 | 28 ± 3 | 1.0000 | | Current smoking, (%) | 7 (38.9%) | 98 (45.2%) | 0.6330 | | HF etiology | | | 0.6598 | | IDCM, (%) | 5 (27.8%) | 76 (35.0%) | | | Dilated IHD, (%) | 8 (44.5%) | 100 (46.1%) | | | Nondilated IHD, (%) | 3 (16.6%) | 28 (12.9%) | | | Other HD, (%) | 2 (11.1%) | 13 (6.0%) | | | NYHA class, (%) | | | 0.8741 | | I | 3 (16.7%) | 30 (13.8%) | | | II | 9 (50.0%) | 98 (45.2%) | | | III | 6 (33.3%) | 86 (39.6%) | | | IV | 0 | 3 (1.4%) | | | VT/VF, (%) | 14 (77.8%) | 87 (40.1%) | 0.0025 | | Comorbidities | | | | | Hypertension, (%) | 12 (66.7%) | 95 (43.8%) | 0.0837 | | Diabetes, (%) | 8 (44.4%) | 82 (37.8%) | 0.6187 | | Dyslipidemia, (%) | 11 (61.1%) | 85 (39.2%) | 0.0827 | | Echo | | | | | LVEDD, (mm) | 58 ± 10 | 61 ± 8 | 0.1354 | | LVESD, (mm) | 47 ± 8 | 48 ± 6 | 0.5093 | | LVEF (%) | 35 ± 10 | 32 ± 11 | 0.2643 |
|
|
BMI: body mass index; HD: heart disease; HF: heart failure; IDCM: idiopathic dilated cardiomyopathy; IHD: ischemic heart disease; LVEDD: left ventricular end-diastolic diameter; LVEF: left ventricular ejection fraction; LVESD: left ventricular end-systolic diameter.
|
